---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-054488"
form_type: "8-K"
ticker: "ASRT"
cik: "0001808665"
company_name: "Assertio Holdings, Inc."
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-14T23:59:45.695363+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Assertio increases acquisition price to $21.80/share all cash; Garda's revised offer up 21.1%

## Summary
- Offer price $21.80/share in cash, no CVR, up from $18 plus CVR (21.1% premium to original offer).
- Premium of 63.1% to unaffected stock price on March 20, 2026; total equity value ~$153.2M.
- Board unanimously approved; tender offer to commence by May 4, 2026; closing expected Q2 2026.
- Financing commitments fully committed: $22.2M equity (Limber and Lund) and up to $130M debt (Colbeck).
- Company withdraws 2026 guidance and cancels Q1 2026 earnings conference call due to pending transaction.

## SEC filing metadata
- accession: 0001104659-26-054488
- form_type: 8-K
- ticker: ASRT
- cik: 0001808665
- company_name: Assertio Holdings, Inc.
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808665/000110465926054488/0001104659-26-054488-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808665/000110465926054488/tm2611405d19_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-054488
- JSON: https://secwatch.observer/filing/0001104659-26-054488.json
- Plain text: https://secwatch.observer/filing/0001104659-26-054488.txt

## Source-grounded claims
- claim_id: d4c8e8db6b38a7e850608e933417d82f61fc2963
  claim: Assertio Holdings, Inc. amended Amended and Restated Agreement and Plan of Merger with Garda Therapeutics, Inc. and Audi Merger Sub, Inc. (effective 2026-05-01).
  evidence_excerpt: On May 1, 2026, Assertio Holdings, Inc. (the “ Company ” or “ Assertio ”) entered into an Amended and Restated Agreement and Plan of Merger (the “ Amended and Restated Merger Agreement ”) with Garda Therapeutics, Inc., a Delaware corporation (“ Parent ”), and Audi Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Purchaser ”), which amends and restates in its entirety the Agreement and Plan of Merger, dated as of April 8, 2026 (the “ Original Merger Agreement ”), by and among the Company, Parent and Purchaser.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1808665/000110465926054488/0001104659-26-054488-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.